Graves' Disease and the Risk of End-Stage Renal Disease: A Korean Population-Based Studyopen access
- Authors
- Cho, YY[Cho, Yoon Young]; Kim, B[Kim, Bongseong]; Shin, DW[Shin, Dong Wook]; Jang, HR[Jang, Hye Ryoun]; Kim, BY[Kim, Bo-Yeon]; Jung, CH[Jung, Chan-Hee]; Kim, JH[Kim, Jae Hyeon]; Kim, SW[Kim, Sun Wook]; Chung, JH[Chung, Jae Hoon]; Han, K[Han, Kyungdo]; Kim, TH[Kim, Tae Hyuk]
- Issue Date
- Apr-2022
- Publisher
- KOREAN ENDOCRINE SOC
- Keywords
- Graves disease; Kidney failure; chronic; Epidemiology; Antithyroid agents
- Citation
- ENDOCRINOLOGY AND METABOLISM, v.37, no.2, pp.281 - 289
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- ENDOCRINOLOGY AND METABOLISM
- Volume
- 37
- Number
- 2
- Start Page
- 281
- End Page
- 289
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/97580
- DOI
- 10.3803/EnM.2021.1333
- ISSN
- 2093-596X
- Abstract
- Background: Hyperthyroidism is associated with an increased glomerular filtration rate (GFR) in the hyperdynamic state, which is reversible after restoring euthyroidism. However, long-term follow-up of renal dysfunction in patients with hyperthyroidism has not been performed. Methods: This was a retrospective cohort study using the Korean National Health Insurance database and biannual health checkup data. We included 41,778 Graves' disease (GD) patients and 41,778 healthy controls, matched by age and sex. The incidences of end-stage renal disease (ESRD) were calculated in GD patients and controls. The cumulative dose and duration of antithyroid drugs (ATDs) were calculated for each patient and categorized into the highest, middle, and lowest textiles. Results: Among 41,778 GD patients, 55 ESRD cases occurred during 268,552 person-years of follow-up. Relative to the controls, regardless of smoking, drinking, or comorbidities, including chronic kidney disease, GD patients had a 47% lower risk of developing ESRD (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.37 to 0.76). In particular, GD patients with a higher baseline GFR (>= 90 mL/min/1.73 m(2); HR, 0.33; 95% CI. 0.11 to 0.99), longer treatment duration (>33 months; HR, 0.31; 95% CI, 0.17 to 0.58) or higher cumulative dose (>16,463 mg; HR, 0.29; 95% CI, 0.15 to 0.57) of ATDs had a significantly reduced risk of ESRD. Conclusion: This was the first epidemiological study on the effect of GD on ESRD, and we demonstrated that GD population had a reduced risk for developing ESRD.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.